Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $126.32M |
| Net Income (Most Recent Fiscal Year) | $-113.72M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -90.03% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -32.43% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.78 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.48 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 0.00 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.35 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.32 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.89 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.90 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 151.01M |
| Free Float | 143.31M |
| Market Capitalization | $94.32M |
| Average Volume (Last 20 Days) | 3.82M |
| Beta (Past 60 Months) | 2.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 59.34% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |